🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Innova Captab Limited INNOVACAP NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://innovacaptab.com

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

READ MORE ›
₹850.40
-1.74% 1Y

Market & Price

Market Cap
₹4,866.41 Cr
Current Price
₹850.40
High / Low (52W)
₹942.66 / ₹642.85
Beta
-0.11

Valuation

Stock P/E
34.48
Industry PE
37.60
Forward P/E
19.07
PEG Ratio
-
Book Value
₹178.28
Price to Book
4.77
P/S
2.99
EV/EBITDA
21.28
Dividend Yield
0.47%

Profitability & Returns

ROCE
15.28%
ROE
13.75%
ROA
7.23%
Profit Margin
8.64%
Op Margin
11.99%
EPS (Latest Qtr)
₹6.65
EPS (TTM)
₹24.66

Balance Sheet & Liquidity

Debt/Equity
0.32
Quick Ratio
0.97
Current Ratio
1.87
Debt
₹343.69 Cr
Total Assets
₹1,837.38 Cr
Current Assets
₹922.96 Cr
Working Capital
₹428.38 Cr

Ownership

Promoter Holding
72.19%
Chg in Prom Hold
-
FII / Inst Holding
19.38%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹5,168.58 Cr
Total Revenue (TTM)
₹1,630.02 Cr
EBITDA
₹242.92 Cr
Free Cash Flow
₹-43.18 Cr
Operating Cash Flow
₹116.51 Cr
Shares Outstanding
₹5.72 Cr
Gross Margin
35.41%
Payout Ratio
8.12%

Growth (CAGR)

Revenue 5Y
20.77%
Profit 5Y
27.52%
Revenue (YoY)
42.30%
Earnings (YoY)
28.60%

PROS

  • Compounding revenue at 20.8% over 5 years.
  • Profit CAGR of 27.5% over 5 years.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INNOVACAP Innova Captab Limited NSEPHARMA 850.40 34.48 ₹4,866.41 Cr 0.47% 15.28% 13.75% 20.77% 27.52%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
Ad space

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 314.74 Cr351.54 Cr380.38 Cr450.29 Cr447.80 Cr
Cost of Revenue 198.02 Cr220.74 Cr243.58 Cr291.82 Cr296.66 Cr
Gross Profit 116.72 Cr130.80 Cr136.80 Cr158.48 Cr151.15 Cr
Operating Expenses 78.83 Cr89.75 Cr96.26 Cr100.50 Cr97.44 Cr
Operating Income 37.88 Cr41.05 Cr40.54 Cr57.97 Cr53.70 Cr
EBITDA 51.06 Cr56.58 Cr56.05 Cr71.05 Cr66.66 Cr
Interest Expense 1.95 Cr2.86 Cr5.50 Cr3.95 Cr4.59 Cr
Pretax Income 39.31 Cr42.68 Cr39.23 Cr55.68 Cr50.67 Cr
Tax Provision 9.74 Cr11.66 Cr9.56 Cr13.53 Cr12.59 Cr
Net Income 29.57 Cr31.02 Cr29.67 Cr42.15 Cr38.08 Cr
Diluted EPS 5.175.425.187.376.65

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -925.40 Cr1,076.96 Cr1,243.68 Cr1,630.02 Cr
Cost of Revenue -701.08 Cr750.51 Cr814.10 Cr1,052.79 Cr
Gross Profit -224.31 Cr326.45 Cr429.58 Cr577.22 Cr
Operating Expenses -119.16 Cr184.92 Cr268.20 Cr379.43 Cr
Operating Income -105.16 Cr141.53 Cr161.38 Cr197.79 Cr
EBITDA -121.81 Cr166.68 Cr198.20 Cr250.34 Cr
Interest Expense -18.94 Cr21.20 Cr2.40 Cr16.90 Cr
Pretax Income -91.80 Cr129.53 Cr171.02 Cr188.26 Cr
Tax Provision -23.84 Cr35.18 Cr42.76 Cr47.35 Cr
Net Income -67.95 Cr94.34 Cr128.26 Cr140.92 Cr
Diluted EPS -11.8718.6622.4124.63

Compounded Sales Growth

5 Years:20.77%
1 Year:42.30%

Compounded Profit Growth

5 Years:27.52%
1 Year:28.60%

Stock Price Performance

1 Year:-1.74%
6 Months:+12.31%
3 Months:+27.02%
1 Month:+18.06%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -704.41 Cr1,320.88 Cr1,580.41 Cr1,837.38 Cr
Current Assets -442.47 Cr579.75 Cr703.11 Cr922.96 Cr
Cash & Equivalents -3.52 Cr11.73 Cr15.52 Cr3.20 Cr
Inventory -117.32 Cr144.02 Cr208.00 Cr283.26 Cr
Receivables -265.22 Cr288.49 Cr331.64 Cr437.29 Cr
Total Liabilities -427.91 Cr489.99 Cr620.99 Cr746.59 Cr
Current Liabilities -277.55 Cr265.48 Cr353.00 Cr494.58 Cr
Long Term Debt -134.18 Cr208.20 Cr243.55 Cr214.80 Cr
Total Debt -236.97 Cr245.10 Cr338.12 Cr343.69 Cr
Total Equity -276.51 Cr830.89 Cr959.42 Cr1,090.79 Cr
Shares Outstanding -5.72 Cr5.72 Cr5.72 Cr5.72 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -67.12 Cr146.34 Cr63.84 Cr116.52 Cr
Investing Cash Flow --90.84 Cr-498.97 Cr-151.59 Cr-107.12 Cr
Financing Cash Flow -27.09 Cr360.83 Cr91.53 Cr-21.71 Cr
Capital Expenditure --78.99 Cr-287.35 Cr-172.50 Cr-68.35 Cr
Free Cash Flow --11.87 Cr-141.01 Cr-108.65 Cr48.16 Cr
Net Change in Cash -3.37 Cr8.20 Cr3.79 Cr-12.32 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -24.2%30.3%34.5%35.4%
Operating Margin % -11.4%13.1%13.0%12.1%
Net Margin % -7.3%8.8%10.3%8.6%
ROE % -24.6%11.4%13.4%12.9%
ROCE % -24.6%13.4%13.1%14.7%

Shareholding Pattern

Insiders
72.19%
Institutions
19.38%
Public Float
69.68%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INNOVACAP

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks